CatalystFDA/Bio

Roche – Hansoh cancer drug deal could exceed $14B

Roche-Hansoh cancer deal exceeding $14B signals major biotech licensing catalyst.

Context

What happened: Hansoh Pharma announced a collaboration and licensing agreement with Roche to develop antibody-drug conjugates, a class of cancer medicines. Key numbers: The deal could be worth more than $14B. Why it matters: The agreement pairs a China-based drugmaker with Roche on a new class of cancer medicines, with potential value above $14B. Coverage: 3 outlets in 24h

What changed

Hansoh Pharma announced a collaboration and licensing agreement with Roche to develop antibody-drug conjugates, a class of cancer medicines.

Why it matters

The agreement pairs a China-based drugmaker with Roche on a new class of cancer medicines, with potential value above $14B.

Sources

seekingalpha